Updates with details, quote
LJUBLJANA, May 23 (Reuters) - Slovenian generic drugs producer Krka KRKG.LJ made a group net profit of 70.3 million euros ($78.4 million) in the first quarter of 2019 versus 49.4 million euros in the same period last year, Krka said in a statement on Thursday.
It said sales rose to 378.5 million euros, up from 338 million a year ago.
Sales in Eastern Europe, Krka's largest market, rose by 15%, while sales in Western Europe were 14% higher.
Krka also confirmed its goals for 2019, which were originally revealed in November, according to which profit is expected to reach at least 172 million euros - on a par with last year's level.
Sales are seen rising to 1.4 billion euros from 1.3 billion last year.
"The management will strive to exceed these goals," the company said in a statement, giving no further details.
Krka is Slovenia's largest listed company with a market capitalisation of 1.9 billion euros.
($1 = 0.8969 euros)
(Reporting by Marja Novak; Editing by Mark Potter)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.